Mounjaro added to the Cyprus GHS list

Starting October 15, 2026, the Health Insurance Organisation (HIO) of Cyprus has officially added Mounjaro to the General Health System (GHS) pharmaceutical list. This change replaces the previous mandatory named-patient request process, which required manual review by specialized committees, with a streamlined pre-approval system governed by uniform protocols.

Under the new guidelines, doctors can submit requests for patients with type 2 diabetes or obesity directly through the GHS system based on specific medical criteria. For obesity treatment, eligibility is divided into two categories: adults with a Body Mass Index (BMI) of 40 or higher, and individuals with a BMI between 35 and 40 who suffer from established atherosclerotic cardiovascular disease or moderate to severe obstructive sleep apnea. Supporting medical documentation remains a requirement for the approval process.

This decision marks a significant shift in medication access for Cypriot patients, aiming to reduce administrative burdens for physicians while standardizing the treatment pathway. The HIO expects this move to facilitate faster and more consistent access to the medication for those meeting the clinical requirements.